<DOC>
	<DOCNO>NCT00106626</DOCNO>
	<brief_summary>The purpose investigational study determine safety tolerability oral suberoylanilide hydroxamic acid administer combination standard dose pemetrexed cisplatin treatment advance solid tumor .</brief_summary>
	<brief_title>Suberoylanilide Hydroxamic Acid Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patient must 18 year old confirm diagnosis solid tumor pemetrexed cisplatin acceptable treatment receive 2 prior systemic therapy Has least 1 measurable lesion Has adequate blood , liver , kidney function Has receive chemotherapy least 4 week prior entry study Agrees take adequate measure prevent pregnancy outline protocol Patient treat investigational agent similar antitumor mechanism Patient Cohorts A B receive pemetrexed cisplatin within past 6 month Cohorts C D receive pemetrexed within past 6 month Patient Cohorts A B preexisting Grade 2 high neuropathy Cohorts C D Grade 3 high neuropathy Patient active infection receive IV ( intravenous ) antibiotic , antiviral , antifungal medication within 2 week start study drug Patient HIV , hepatitis B hepatitis C infection Patient pregnant breast feeding Patient allergy component study drug Patient history GI ( gastrointestinal ) surgery condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Advanced solid tumor include MPM NSCLC</keyword>
</DOC>